• suivant http://www.cornerstonepg.com/l...medicament montrer medicament xylocaine 1 toile
    1. http://www.westkern-oilmuseum.org/ go web go to http://www.westkern-oilmuseum.org/
    pagina site tela page netz
    clic clic clic mas aller

    Head and neck cancer in Canada: trends 1992 to 2007

    Sun, Feb 12, 2012

    Oral Cancer News

    Source: oto.sagepub.com/
    Authors: Johnson-Obaseki et al.

    The objective of this study was to investigate the changes in the epidemiology (incidence, age at diagnosis, and survival) of head and neck cancers (HNCs) in Canada in the past decade.

    Study Design:
    Analysis of a national cancer data registry.

    All Canadian hospital institutions treating head and neck cancer.

    Subjects and Methods.
    Using Canadian Cancer Registry data (1992-2007), the authors categorized HNCs into 3 groups according to their possible association with human papillomavirus (HPV): oropharynx (highly associated), oral cavity (moderate association), and “other” (hypopharynx, larynx, and nasopharynx), which are not HPV related. They calculated age-adjusted incidence, median age at diagnosis, and survival for each category.

    Oropharynx tumors increased in incidence over the study time period (annual percent change: 1.50% men, 0.8% women), whereas oral cavity tumors decreased (2.10% men, 0.4% women), as did other HNCs (decreased by 3.0% for men and 1.9% for women). The median age at diagnosis for oropharynx cancer decreased by an average of 0.23 years/y. There was no change for oral cavity tumors but an increase for other HNCs of 0.12 years/y. Survival for patients with oropharynx cancer increased by 1.5%/y but was significant for men only. Survival for patients with oral cavity and other HNCs also increased in men only by 0.9%/y and 0.25%/y, respectively.

    Oropharynx cancer, which is highly correlated with HPV infection, is increasing in incidence in Canada, with a decreasing age at diagnosis and an improvement in survival. This could have implications for screening strategies and treatment for oropharyngeal cancers in Canada.

    Stephanie Johnson-Obaseki, MD, FRCSC 1
    James Ted McDonald, PhD 2
    Martin Corsten, MD, FRCSC 3
    Ryan Rourke, MD3

    Authors’ affiliations:
    1 Department of Otolaryngology–Head and Neck Surgery, University of Toronto, Toronto, Canada
    2 Department of Economics, University of New Brunswick, New Brunswick, Canada
    3 Department of Otolaryngology–Head and Neck Surgery, University of Ottawa, Ottawa, Canada

    Print Friendly
    Be Sociable, Share!

    Leave a Reply

    You must be logged in to post a comment.